Roundhill NVDA WeeklyPay ETF vs ResMed Inc. — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.14 (market cap $119.10M), while ResMed Inc. trades at $230.78 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 267.8× Roundhill NVDA WeeklyPay ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 50 Days and ResMed Inc. for 51 Days on average.
| NVDW | RMD | |
|---|---|---|
Market Cap | $119.10M | $31.89B |
Volume | 44,838 | 618,314 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $277.88 |
52-Week Low | $31.88 | $182.82 |
Typical Hold Time | 50 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →